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Abstract
Piracetam is a positive allosteric modulator of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor that
has been frequently used in the treatment of cognitive disorders. Press and internet reports indicate that the use of
piracetam, as a heroin adulterant, has spread rapidly in some countries, especially in Asia and Europe. Its use, as
adulterant, is believed to produce more profound desirable effects, while decreasing hangover. Recent surveys demon-
strated that piracetam protects neurons from heroin-induced apoptosis. The protective role of this adulterating sub-
stance may be related to restoration of beta-endorphin levels and to its neuroprotective effects. The aim of this paper is
to review the relevant literature and suggest the main hypothetical mechanisms that justify its use as a heroin adulterant,
try to understand if its use could help people who want to come off heroin by reducing withdrawal symptoms and, finally,
give useful information that permit us to understand why drug trafficking organisations started to use piracetam as heroin
adulterant.
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Introduction
Piracetam (PIR), IUPAC name 2-(2-oxopyrrolidin-1-
yl)-acetamide, is a positive allosteric modulator of the
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor, which improves behaviour, cogni-
tive and memory functions and has been used as ‘cog-
nitive enhancer’ clinically for decades.1 Press and
internet reports indicate that the use of PIR, as a
heroin adulterant, has spread rapidly in some countries,
especially in Asia and Europe.2 Its use, as adulterant, is
believed to produce more profound desirable effects,
while decreasing hangover.
The use of PIR as a heroin adulterant has been
reported in literature for a brief period, but there has
been no attempt to explain how it works.3,4
Thus far, its addictive properties and potential
effects to the central neural system are not known.
Recent surveys demonstrated that PIR protects
neurons from heroin-induced apoptosis. The protective
role of this adulterating substance may be related to
restoration of beta-endorphin levels and to its
neuroprotective effects. This paper aims to review the
relevant literature and suggest the main hypothetical
mechanisms that justify its use as a heroin adulterant,
try to understand if its use could help people who want
to come off heroin by reducing withdrawal symptoms
and, finally, offer some explanation on why drug traf-
ficking organisations have started using PIR as heroin
adulterant.
Uses of PIR
PIR is a member of the class of prescription drugs
known as nootropics or ‘smart drugs’ and it is sold
1Legal Medicine Section – SAIMLAL Department, SAPIENZA University
of Rome, Roma, Italy
2State Police Health Service Department, Ministry of Interior, Rome, Italy
Corresponding author:
Simone Cappelletti, Legal Medicine Section – SAIMLAL Department,
SAPIENZA University of Rome, Viale Regina Elena, 336, 00161 Roma,
Italy.
Email: simone.cappelletti@uniroma1.it
Medico-Legal Journal
0(0) 1–4
! The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0025817217717846
journals.sagepub.com/home/mlj
under many brand names like BreinoxTM, LucetamTM,
NootropilTM, OikamidTM or PiracetamTM.5 It is a posi-
tive allosteric modulator of the AMPA receptor, which
improves behaviour, cognitive and memory functions.
Its use as ‘cognitive enhancer’ and potential treatment
for neurological diseases has been known for decades.
It has been widely used as a long-term treatment for
clotting, coagulation and vasospastic disorders.
In the United States, PIR is not approved by the US
Food and Drug Administration (FDA) for any medical
use and may not be sold as a dietary supplement. In
Europe, it is often used off-label for many conditions
and as a dietary supplement. It is possible to buy PIR
supplements, either in powder or in pill form online and
in a pharmacy with a medical prescription. The average
price per dose when purchasing PIR is $0.30, making
this one of the cheapest nootropics available for sale.
Safety data on PIR have demonstrated that it has a low
toxicity potential. Single doses of PIR yielded LD50
values at 26 g/kg in mice but LD50 values were not
reached in rats. In dogs, clinical signs after acute oral
dosing were mild and lethality was not observed at the
maximum tested dose of 10 g/kg; no tests were con-
ducted on humans.
The FDA has a very strict definition for what qua-
lifies as a dietary supplement. This policy is laid out in
section 201 of the Food, Drug and Cosmetic Act, 21
U.S.C. § 321. It states that a dietary supplement must
be one of the following: a vitamin, mineral, amino acid,
herbal extract, botanical compound or a concentrate,
metabolite, constituent, extract or combination of a
dietary ingredient. PIR is none of these things and
therefore does not qualify as a supplement under
FDA regulations. FDA considers, PIR to be pharma-
cologically active and so categorises it as a ‘drug’ but
has not approved PIR as a nootropic compound
because the FDA only gives regulatory approval to
drugs intended to diagnose, treat, cure, or prevent dis-
eases. PIR, at present, does not fall within the FDA’s
policy definition.
PIR mechanisms of action
The most accredited theories explaining how PIR
works are:
. influence on level of dopamine;
. interaction with glutamatergic system;
. allosteric modulation of glutamatergic AMPA
receptors;
. interaction with membrane phospholipids.
On the issue of dopamine action, animal studies have
shown that PIR interferes with dopamine levels
by increasing the stimulated dopamine release.6
By contrast, lower doses of PIR demonstrated no sign-
iEcant inFuence on the dopaminergic brain activity.6,7
The PIR interaction with the glutamatergic system is
not yet fully understood. As the glutamatergic system
impairment was described in cognitive deEcits,6,8 it is
possible that glutamatergic effects of PIR contribute to
its positive impact on cognition. Furthermore, PIR has
an important role in the allosteric modulation of gluta-
matergic AMPA receptors,9 structures involved in posi-
tive reinforcement in addiction.10
The PIR interaction with membrane phospholipids
is the most accredited mechanism of action on the
activities of neurotransmitter systems.11 It is well
known that neurotransmitter signals depend on binding
to speciEc membrane protein structures, such as recep-
tors and transporters. The PIR effect on the membrane
fluidity could have a significant impact on binding sites
for neurotransmitters and could, indirectly, affect their
functioning.12
Heroin–PIR known mechanisms
of interaction
The interaction between heroin and PIR may be
explained in two different mechanisms.
The first, proposed by Wang et al,13 focuses on the
hypoxic-ischemic brain damage and neuroinflamma-
tory response that heroin causes to the central nervous
system. It is well known that hypoxic-ischemic damage
induces the release of chemokines, cytokines and other
inflammatory mediators by the activation of leuco-
cytes,14 endothelial and glial cells,15 especially microglia
which is the predominant immune-competent cell type
of the central nervous system.16 In response to these
neurotoxic effects, PIR seems to increase activity of
phospholipase A2, an intracellular messenger import-
ant in the production of arachidonic acid within the
neuron. In turn, arachidonic acid is converted into
prostaglandins, which can modulate neuronal excitabil-
ity in a very general sort of way and thereby contribute
to modulation of synaptic transmission.17 In studies
examining neural injury in mice due to insufficient
brain oxygenation, PIR has been shown to exert neu-
roprotective effects, indeed it increases synthesis of
phospholipids, which help to protect neuronal and
other brain membranes damages. The increase in
synthesis of phospholipids requires high-energy com-
pounds, for this reason, PIR increases energy reserves
under reduced oxygen by maintaining normal adeno-
sine triphosphate production.17
The second mechanism reported by Roth-Deri
et al.18 is related to the opioid-receptor agonist action
of heroin, that affect the levels of endogenous opioid
peptides such as the beta-endorphin. Recent animal
studies demonstrated that chronic heroin use resulted
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in a significant reduction of beta-endorphins, and in a
heroin-induced neuronal apoptosis in the medial pre-
frontal cortex and nucleus accumbens within the corti-
colimbic system. The same authors showed how the
treatment with PIR normalised the beta-endorphin
levels and the neuronal morphologies in the above-
mentioned areas.19,20 These results imply that the neu-
roprotective role of PIR in heroin-induced apoptosis
might be related to the restoration of beta-endorphin
levels.
These mechanisms may affect the intensity and dur-
ation of heroin withdrawal symptoms. This was also
confirmed in a paper by Chaudhry et al.,21 in which
the authors analysed aches and pains, fatigue and
drowsiness among two heroin addicted groups treated
with PIR and placebo, respectively. They concluded
that in the group treated with PIR, the said symptoms
disappeared more quickly than in the placebo group,
confirming a possible role for PIR in heroin users.
The aforementioned mechanisms of action could
affect drug users differently. For example, there is
some evidence to suggest that PIR could help people
who want to come off heroin and reduce withdrawal
symptoms. However, there is no definitive data on this,
but it is possible that it may be useful and more
research is indicated.
Drug trafficking organisations appear to use this
mixture to encourage drug use by its effect of reducing
the malign consequences for the user which would
explain why the supply of heroin adulterated with
PIR has spread rapidly in recent years.
Conclusion
The use of PIR as an adulterant needs more study to
enable us to have a clearer understanding of how it
works. Preliminary hypotheses have been put forward
and we have summarised the ways in which we believe
PIR may operate to reduce the effects of heroin on the
central nervous system (Figure 1).
The results of the study suggest that the combination
of heroin–PIR makes drug addicts feel more comfort-
able and suffer fewer side effects. There is a danger that
heroin addicts might misinterpret this type of drug mix-
ture as ‘good heroin’. In particular, these studies
demonstrated that this mixture, even in low doses,
improves heroin’s reward properties and reduces its
effects on the central nervous system.
That said, it seems to us there is real potential to use
the combination to assist people to withdraw from
heroin addiction more easily with fewer ill effects. The
other side of the coin is that the option of withdrawal
may seem less attractive if continued heroin use is less
destructive to the addict.
Further, we need to understand why drug trafficking
organisations are using PIR as a heroin adulterant, and
these studies offer a useful starting point. But further
research on this topic is needed.
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